✦ LIBER ✦

The level of HER2/neu gene amplification as predictive factor in patients with metastatic breast cancer treated with a trastuzumab-based therapy

✍ Scribed by G. Gullo; D. Bettio; V. Torri; G. Masci; P. Salvini; A. Santoro

Book ID: 119598390
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 59 KB
Volume: 6
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(08)70899-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phosphorylated HER-2 tyrosine kinase and

Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC)

✍ Rosa Giuliani; Virginie Durbecq; Angelo Di Leo; Marianne Paesmans; Denis Larsimo 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 636 KB

Serum HER-2/neu and relative resistance

Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer

✍ Suhail M. Ali; Walter P. Carney; Francisco J. Esteva; Monica Fornier; Lyndsay Ha 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 175 KB 👁 2 views

Her-2/neu and EGFR tyrosine kinase activ

Her-2/neu and EGFR tyrosine kinase activation predict the efficacy of trastuzumab-based therapy in patients with metastatic breast cancer

✍ Gernot Hudelist; Wolfgang J. Köstler; Klaus Czerwenka; Ernst Kubista; Johannes A 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 French ⚖ 372 KB 👁 2 views

## Abstract Her‐2/__neu__ overexpression in human breast cancer leads to an aggressive biological behavior and poor prognosis. Although the anti‐Her‐2/__neu__ antibody trastuzumab (Herceptin®) has become a valuable therapeutic option for patients with Her‐2/__neu__‐overexpressing breast cancer, man

Clinical utility of serum HER2/neu in mo

Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies

✍ Francisco J Esteva, Carol D Cheli, Herbert Fritsche… 📂 Article 📅 2005 🏛 BioMed Central 🌐 English ⚖ 195 KB

Quantitative HER2 protein levels predict

Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab

✍ Allan Lipton; Wolfgang J. Köstler; Kim Leitzel; Suhail M. Ali; Jeff Sperinde; Jo 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 492 KB 👁 2 views

## Abstract ## BACKGROUND: Only a portion of breast cancer patients currently selected for trastuzumab therapy respond. ## METHODS: Using a novel assay (HERmark) to quantify total human epidermal growth factor receptor 2 (HER2) expression, the authors examined outcomes in 102 trastuzumab‐treated

KI67 and p53 are not predictive of tumor

KI67 and p53 are not predictive of tumor response or survival with trastuzumab-based therapy in metastatic breast cancer patients (pts) with her2/neu-overexpression

✍ A. Schneeweiss; F. Lenz; F. Beldermann; M. Geberth; R. Goerner; P. Sinn; H.-J. S 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 171 KB